# Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Source: https://onco.cc/trials/nct05103358/  
OnCo record `nct05103358` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sirolimus protein-bound particles in metastatic cancer, run by Aadi Bioscience, Inc., active and no longer recruiting.

## Summary

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) is a phase 2 interventional study registered as NCT05103358 by Aadi Bioscience, Inc., with 120 participants planned, started 2022-02-15 and due to reach its primary completion in 2024-12-31. Interventions recorded: nab-sirolimus. Conditions listed: Tumor, Tumor, Solid, Metastasis, Metastatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05103358
- Phase: 2
- Setting: A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
- Sponsor: Aadi Bioscience, Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05103358: https://clinicaltrials.gov/study/NCT05103358

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Sirolimus protein-bound particles](https://onco.cc/drugs/sirolimus-albumin-bound/)

---
JSON: https://onco.cc/api/v1/entities/nct05103358.json